Irvine, California, June 15, 2017 – Algae Health Sciences, Inc. (AlgaeHealth), a subsidiary of BGG, announced today a positive clinical trial publication at the American College of Sports Nutrition for AstaZine® Natural Astaxanthin. Results showed a reduction in heart rate by 10% during long distance running (Talbott, et al, 2017*). “We found a very novel effect of natural astaxanthin to improve overall cardiovascular function,” said Shawn Talbott, PhD, the lead researcher. “The subjects in this study were able to perform the same amount of ‘work’—but at lower cardiovascular ‘strain’ after supplementing with astaxanthin.” BGG’s CEO, Yanmei Li, PhD added, “The implications of this study for athletes as well as potential benefits for anyone concerned with cardiovascular health are immense. We plan to publish this result in conjunction with some other exciting clinical results in a strong peer-reviewed journal later this year.”

In addition, the AstaZine® Natural Astaxanthin product line has attained self-affirmed GRAS status (Generally Recognized As Safe). This accomplishment comes after a quick series of regulatory achievements in regions as diverse as USA, Europe and Australia. “We are extremely pleased to attain this important milestone to enable more extensive use of AstaZine® in the US food and beverage markets,” said Peinan Zhang, Director of Quality and Regulatory for AlgaeHealth’s parent company BGG.

Algae Health Sciences, Inc., a subsidiary of BGG, focuses on the production and marketing of efficacious ingredients from natural algae sources. With the second largest capacity to produce Natural Astaxanthin from microalgae, Algae Health Sciences plans to become the world’s largest Astaxanthin producer in 2018. The company has facilities in USA, Switzerland, Japan and China.